Jasper Therapeutics, Inc. (JSPR) Form 8-K — Jul 16, 2026

$JSPRForm 8-KItems 1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 9.01Filed Jul 16, 2026, 9:50 PM ET0001213900-26-078887Original filing

Jasper Therapeutics completed its acquisition of Kira Pharmaceuticals on July 16, 2026, issuing approximately 5.2 million shares of common stock and 4.6 million shares of convertible preferred stock to Kira shareholders. The transaction, structured as a tax-free reorganization, grants Kira shareholders a majority stake (approximately 88.7% pre-financing) and includes a Contingent Value Right (CVR) agreement worth $30 million if the FDA issues a Priority Review Voucher for briquilimab by the end of 2028.

Key figures

Gross Proceeds: $132 million
Shares Offered: approximately 4.7 million
Cvr milestone payment: $30.0 million
Mirador upfront payment: $12,000,000
Preferred conversion ratio: 61:1
Merger common shares issued: 5195009
Mirador commercial milestones: $350,000,000
Post financing kira ownership: 49.86%
Merger preferred shares issued: 4644977
Mirador development milestones: $108,500,000
Post financing jasper ownership: 6.68%

Price after filing

1 day: +14.3%7 days: -5.8%30 days: +2.1%

Close on the filing date to close N calendar days later (from $0.77). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.